Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AZN Astrazeneca plc
- Stocks
- Healthcare
- NASDAQ: AZN
Price (delayed)
$69.68
Market cap
$216.01B
P/E Ratio
27.76
Dividend/share
$1.55
EPS
$2.51
Enterprise value
$242.42B
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.
Highlights
AZN's price to earnings (P/E) is 78% lower than its 5-year quarterly average of 125.9 and 16% lower than its last 4 quarters average of 33.2
The company's gross profit rose by 33% QoQ and by 13% YoY
AZN's debt is down by 8% year-on-year but it is up by 4.5% since the previous quarter
The quick ratio has declined by 4.3% since the previous quarter and by 2.9% year-on-year
Key stats
What are the main financial stats of AZN
Market
Valuations
Earnings
Shares outstanding
3.1B
Market cap
$216.01B
Enterprise value
$242.42B
Price to earnings (P/E)
27.76
Price to book (P/B)
5.27
Price to sales (P/S)
3.15
EV/EBIT
22.12
EV/EBITDA
13.71
EV/Sales
3.54
Revenue
$68.5B
Gross profit
$58.27B
Operating income
$24.08B
Net income
$7.77B
EBIT
$10.96B
EBITDA
$17.68B
Free cash flow
$11.16B
Per share
Balance sheet
Liquidity
EPS
$2.51
EPS diluted
$2.49
Free cash flow per share
$3.6
Book value per share
$13.23
Revenue per share
$22.1
TBVPS
$15.35
Total assets
$106.25B
Total liabilities
$65.12B
Debt
$31.65B
Equity
$41.04B
Working capital
-$2.99B
Debt to equity
0.77
Current ratio
0.9
Quick ratio
0.67
Net debt/EBITDA
1.49
Margins
Efficiency
Dividend
EBITDA margin
25.8%
Gross margin
85.1%
Net margin
11.3%
Operating margin
35.1%
Return on assets
7.4%
Return on equity
19.2%
Return on invested capital
25.1%
Return on capital employed
14.2%
Return on sales
16%
Dividend yield
2.22%
DPS
$1.55
Payout ratio
61.8%
AZN stock price
How has the Astrazeneca stock price performed over time
Intraday
-1.22%
1 week
-1.53%
1 month
-1.04%
1 year
-12.63%
YTD
6.35%
QTD
-5.2%
Financial performance
How have Astrazeneca's revenue and profit performed over time
Revenue
$68.5B
Gross profit
$58.27B
Operating income
$24.08B
Net income
$7.77B
Gross margin
85.1%
Net margin
11.3%
AZN's operating income has surged by 141% since the previous quarter and by 13% year-on-year
The operating margin has soared by 90% from the previous quarter
The company's gross profit rose by 33% QoQ and by 13% YoY
Astrazeneca's revenue has increased by 27% QoQ and by 14% YoY
Price vs fundamentals
How does AZN's price correlate with its fundamentals
Growth
What is Astrazeneca's growth rate over time
Valuation
What is Astrazeneca stock price valuation
P/E
27.76
P/B
5.27
P/S
3.15
EV/EBIT
22.12
EV/EBITDA
13.71
EV/Sales
3.54
AZN's price to earnings (P/E) is 78% lower than its 5-year quarterly average of 125.9 and 16% lower than its last 4 quarters average of 33.2
Astrazeneca's EPS has increased by 22% YoY and by 11% QoQ
The stock's price to book (P/B) is 20% less than its 5-year quarterly average of 6.6 and 6% less than its last 4 quarters average of 5.6
AZN's equity is up by 10% year-on-year
The stock's price to sales (P/S) is 32% less than its 5-year quarterly average of 4.6 and 15% less than its last 4 quarters average of 3.7
Astrazeneca's revenue has increased by 27% QoQ and by 14% YoY
Efficiency
How efficient is Astrazeneca business performance
Astrazeneca's return on sales has decreased by 17% QoQ but it has increased by 6% YoY
The return on assets is up by 16% year-on-year and by 9% since the previous quarter
The company's return on equity rose by 14% YoY and by 8% QoQ
Astrazeneca's return on invested capital has increased by 2.9% QoQ
Dividends
What is AZN's dividend history
DPS
$1.55
Dividend yield
2.22%
Payout ratio
61.8%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Astrazeneca financials performed over time
The company's total assets is 63% higher than its total liabilities
The company's total assets rose by 3.9% YoY and by 2.1% QoQ
The quick ratio has declined by 4.3% since the previous quarter and by 2.9% year-on-year
AZN's debt is 23% smaller than its equity
AZN's debt to equity is down by 16% year-on-year but it is up by 4.1% since the previous quarter
AZN's equity is up by 10% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.